Search

Objective: The goal of this paper was to optimize robust PID control for propofol anesthesia in children aged 5–10 years to improve performance, particularly to decrease the time of induction of anesthesia while maintaining robustness. Methods: We analyzed results of a previous study conducted by our group to identify opportunities for system improvement. Allometric scaling was introduced to reduce the interpatient variability and a new robust PID controller was designed using an optimization-based method. We evaluated this optimized design in a clinical study involving 16 new cases. Results: The optimized controller design achieved the performance predicted in simulation studies in the design stage. Time of induction of anesthesia was median [Q1, Q3] 3.7 [2.3, 4.1] min and the achieved global score was 13.4 [9.9, 16.8]. Conclusion: Allometric scaling reduces the interpatient variability in this age group and allows for improved closed-loop performance. The uncertainty described by the model set, the predicted closed-loop responses, and the predicted robustness margins are realistic. The system meets the design objectives of improved speed of induction of anesthesia while maintaining robustness and improving clinically relevant system behavior. Significance: Control system optimization and ongoing system improvements are essential to the development of a clinically relevant commercial device. This paper demonstrates the validity of our approach, including system modeling, controller optimization, and pre-clinical testing in simulation. [ABSTRACT FROM AUTHOR]

This paper describes the design and evaluation of a controller for multi-input single-output (MISO) propofol-remifentanil anesthesia, guided by feedback from a measure of depth-of-hypnosis (DOH). DOH monitors are commonly used in clinical practice to guide anesthetic dosing, however, there is currently no widely accepted nociception monitor to guide remifentanil (analgesic) infusion. Variability in the DOH measure has been associated with insufficient analgesia, and feasibility of closed-loop control of both propofol and remifentanil infusion using DOH feedback has been demonstrated. However, DOH variability does not provide a measure of analgesia in the absence of stimulation. Consequently, control of the opioid-hypnotic balance is lost in control systems relying on DOH feedback alone. The proposed design overcomes this limitation by introducing a second, indirect control objective. This paper defines clinical design specifications to achieve adequate anesthesia in a wide range of clinical cases, proposes a modification of the habituating control framework, and presents methods to translate the clinical objectives into control objectives within this framework. The developed design methodology provides a controller that: 1) meets the clinical objectives; 2) is robust to interpatient variability, both in single-input single-output and MISO operation; 3) is robust to nonlinear drug interactions; 4) gives the user control of the opioid-hypnotic balance in the absence of stimulation and in the presence of input saturation; and 5) improves disturbance rejection following nociceptive stimulation. The MISO system performed as designed in 80 clinical cases. [ABSTRACT FROM AUTHOR]

This paper describes the design of a robust proportional-integral derivative (PID) controller for propofol infusion in children and presents the results of clinical evaluation of this closed-loop system during endoscopic investigations in children age 6–17. The controller design is based on a set of models that describes the interpatient variability in the response to propofol infusion in the study population. The PID controller is tuned to achieve sufficient robustness margins for the identified uncertainty. 108 children were enrolled in this study, and anesthesia was closed-loop controlled in 102 of these cases. Clinical evaluation of the system shows that closed-loop control of both induction and maintenance of anesthesia in children based on the WAVCNS index as a measure of clinical effect is feasible. A robustly tuned PID controller can accommodate the interpatient variability in children and spontaneous breathing can be maintained in most subjects. [ABSTRACT FROM AUTHOR]

Closed-loop control of anesthesia is expected to decrease drug dosage and wake up time while increasing patient safety and decreasing the work load of the anesthesiologist. The potential of closed-loop control in anesthesia has been demonstrated in several clinical studies. One of the challenges in the development of a closed-loop system that can be widely accepted by clinicians and regulatory authorities is the effect of interpatient variability in drug sensitivity. This system uncertainty may lead to unacceptable performance, or even instability of the closed-loop system for some individuals. The development of reliable models of the effect of anesthetic drugs and characterization of the uncertainty is, therefore, an important step in the development of a closed-loop system. Model identification from clinical data is challenging due to limited excitation and the lack of validation data. In this paper, approximate models are validated for controller design by evaluating the predictive accuracy of the closed-loop behavior. A set of 47 validated models that describe the interpatient variability in the response to propofol in children is presented. This model set can be used for robust linear controller design provided that the experimental conditions are similar to the conditions during data collection. [ABSTRACT FROM PUBLISHER]

• PID structure as a limiting factor in closed-loop propofol anaesthesia is analysed. • Optimal higher-order LTI controllers are represented using the Youla parameter. • A higher-order controller does not markedly improve the performance versus a PID. • Inter-patient variability is the most substantial limitation to control performance. Background and Objective: New proposals to improve the regulation of hypnosis in anaesthesia based on the development of advanced control structures emerge continuously. However, a fair study to analyse the real benefits of these structures compared to simpler clinically validated PID-based solutions has not been presented so far. The main objective of this work is to analyse the performance limitations associated with using a filtered PID controller, as compared to a high-order controller, represented through a Youla parameter. Methods: The comparison consists of a two-steps methodology. First, two robust optimal filtered PID controllers, considering the effect of the inter-patient variability, are synthesised. A set of 47 validated paediatric pharmacological models, identified from clinical data, is used to this end. This model set provides representative inter-patient variability Second, individualised filtered PID and Youla controllers are synthesised for each model in the set. For fairness of comparison, the same performance objective is optimised for all designs, and the same robustness constraints are considered. Controller synthesis is performed utilising convex optimisation and gradient-based methods relying on algebraic differentiation. The worst-case performance over the patient model set is used for the comparison. Results: Two robust filtered PID controllers for the entire model set, as well as individual-specific PID and Youla controllers, were optimised. All considered designs resulted in similar frequency response characteristics. The performance improvement associated with the Youla controllers was not significant compared to the individually tuned filtered PID controllers. The difference in performance between controllers synthesized for the model set and for individual models was significantly larger than the performance difference between the individual-specific PID and Youla controllers. The different controllers were evaluated in simulation. Although all of them showed clinically acceptable results, the robust solutions provided slower responses. Conclusion: Taking the same clinical and technical considerations into account for the optimisation of the different controllers, the design of individual-specific solutions resulted in only marginal differences in performance when comparing an optimal Youla parameter and its optimal filtered PID counterpart. The inter-patient variability is much more detrimental to performance than the limitations imposed by the simple structure of the filtered PID controller. [ABSTRACT FROM AUTHOR]